Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL589 | 0.92 | TSHR (0.31) | TSHRTDP1ALDH1A1 | |
| Potassium Ion SCHEMBL3889958 | 0.92 | TSHR (0.31) | TSHRTDP1ALDH1A1 | |
| SCHEMBL107947 | 0.92 | ALDH1A1 (0.36) | TSHRTDP1ALDH1A1 | |
| Lithium Ion SCHEMBL2059893 | 0.89 | — | — | |
| Lithium Ion SCHEMBL9293254 | 0.89 | — | — | |
| Lithium Ion SCHEMBL9293243 | 0.89 | — | — | |
| Lithium Ion SCHEMBL14812375 | 0.89 | — | — | |
| Lithium SCHEMBL30686180 | 0.88 | ALDH1A1 (0.33) | TSHRTDP1ALDH1A1 | |
| SCHEMBL1939142 | 0.88 | ALDH1A1 (0.33) | TSHRTDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28815855 | 0.88 | ALDH1A1 (0.33) | TSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0179559-A2 | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | claimed |
| EP-2546243-B1 | METHOD FOR PREPARING ALISKIREN | ZHEJIANG TIANYU PHARMACEUTICAL CO LTD (CN) | 2015-01-07 | — | — | EP | disclosed |
| US-8664440-B2 | Method for preparing aliskiren and its intermediates thereof | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD (CN) | 2014-03-04 | — | — | US | disclosed |
| US-20130225841-A1 | METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| EP-2546243-A1 | METHOD FOR PREPARING ALISKIREN AND INTERMEDIATE THEREOF | Zhejiang Tianyu Pharmaceutical Co., Ltd (CN) | 2013-01-16 | — | — | EP | disclosed |
| US-7572303-B2 | A symmetrical dialkyl carbonate, a metal, borong, silicon, or group 7 compound, a hydrogen or hydrocarbon-based fuel, an oxidizer, and a metallic cocatalyst; minimized hydrolysis; improved combustion and storage stability | OCTANE INTERNATIONAL, LTD. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| EP-0954558-B1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050044778-A1 | Fuel compositions employing catalyst combustion structure | OCTANE INTERNATIONAL, LTD. | 2005-03-03 | — | — | US | disclosed |
| US-20040237384-A1 | Fuel compositions exhibiting improved fuel stability | OCTANE INTERNATIONAL, LTD. | 2004-12-02 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5606078-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-4737496-A | ANXIOLYTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-04-12 | — | — | US | disclosed |
| US-4595535-A | Schizophrenia | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | disclosed |
| US-4507311-A | Imidazo[1,2-c][1,3]benzodiazepines | CIBA-GEIGY CORPORATION (US) | 1985-03-26 | — | — | US | disclosed |
| US-4460587-A | ANTIPSYCHOTIC AGENTS, ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| US-3954811-A | PROSTAGLANDIN INTERMEDIATES | SUMITOMO CHEMICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225841-A1 | METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF | FLI1, MLX, LMTK2 | TSHR 1471/4885TDP1 3676/4885ALDH1A1 4186/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | TSHR 876/4885TDP1 821/4885ALDH1A1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.